Richard A. Waldron net worth and biography

Richard Waldron Biography and Net Worth

CFO of BioAtla

Mr. Waldron has extensive experience in the financing and executive operations of biotechnology companies. He has served as the Chief Financial Officer of three publicly traded companies, successfully raising capital for all three and executing the merger of one of them. Prior to working in the industry Mr. Waldron served as a senior health care banker, executing public and private financings and strategically significant transactions for clients including Genzyme and Genentech. He initiated the health care sector banking practice at Cowen & Company. He graduated with honors from Harvard Business School, and magna cum laude from Princeton University.

How old is Richard A. Waldron?: Mr. Waldron is currently 70 years old. There are 3 older executives and no younger executives at BioAtla. Learn More on Richard A. Waldron's age.
How do I contact Richard A. Waldron?: The corporate mailing address for Mr. Waldron and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected]. Learn More on Richard A. Waldron's contact information.
Has Richard A. Waldron been buying or selling shares of BioAtla?: Richard A. Waldron has not been actively trading shares of BioAtla within the last three months. Most recently, Richard A. Waldron sold 7,246 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $23.03, for a transaction totalling $166,875.38. Learn More on Richard A. Waldron's trading history.
Who are BioAtla's active insiders?: BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.
Are insiders buying or selling shares of BioAtla?: During the last year, BioAtla insiders bought shares 3 times. They purchased a total of 74,000 shares worth more than $157,320.00. The most recent insider tranaction occured on December, 26th when Director Sylvia Mcbrinn bought 4,000 shares worth more than $9,320.00. Insiders at BioAtla own 11.5% of the company. Learn More about insider trades at BioAtla.
Information on this page was last updated on 12/26/2023.

Richard A. Waldron Insider Trading History at BioAtla

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/1/2021	Sell	7,246	$23.03	$166,875.38
11/29/2021	Sell	4,599	$23.89	$109,870.11
11/24/2021	Sell	3,937	$24.87	$97,913.19
11/22/2021	Sell	3,626	$26.23	$95,109.98

Richard A. Waldron Buying and Selling Activity at BioAtla

BioAtla Company Overview

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.18

$1.17

$1.34

50 Day Range

MA: $1.78

$1.18

$2.37

2 Week Range

Now: $1.18

$1.14

$4.02

Volume

871,695 shs

Average Volume

840,682 shs

Market Capitalization

$57.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.